- Home
- ABVX vs CVAC Comparison
ABVX vs CVAC Comparison
Compare ABVX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- CVAC
- Stock Information
- Founded
- ABVX 2013
- CVAC 2000
- Country
- ABVX France
- CVAC Germany
- Employees
- ABVX N/A
- CVAC N/A
- Industry
- ABVX
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- ABVX
- CVAC Health Care
- Exchange
- ABVX Nasdaq
- CVAC Nasdaq
- Market Cap
- ABVX 511.3M
- CVAC 1.2B
- IPO Year
- ABVX N/A
- CVAC 2020
- Fundamental
- Price
- ABVX $8.85
- CVAC $5.41
- Analyst Decision
- ABVX Buy
- CVAC Hold
- Analyst Count
- ABVX 4
- CVAC 3
- Target Price
- ABVX $31.50
- CVAC $6.83
- AVG Volume (30 Days)
- ABVX 381.0K
- CVAC 974.0K
- Earning Date
- ABVX 08-11-2025
- CVAC 08-14-2025
- Dividend Yield
- ABVX N/A
- CVAC N/A
- EPS Growth
- ABVX N/A
- CVAC N/A
- EPS
- ABVX N/A
- CVAC 0.87
- Revenue
- ABVX $11,444,012.00
- CVAC $566,039,775.00
- Revenue This Year
- ABVX $284.20
- CVAC N/A
- Revenue Next Year
- ABVX N/A
- CVAC $24.04
- P/E Ratio
- ABVX N/A
- CVAC $6.26
- Revenue Growth
- ABVX 128.98
- CVAC 787.60
- 52 Week Low
- ABVX $4.77
- CVAC $2.37
- 52 Week High
- ABVX $14.16
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- ABVX 72.74
- CVAC 61.38
- Support Level
- ABVX $7.70
- CVAC $5.42
- Resistance Level
- ABVX $8.56
- CVAC $5.49
- Average True Range (ATR)
- ABVX 0.50
- CVAC 0.07
- MACD
- ABVX 0.13
- CVAC -0.06
- Stochastic Oscillator
- ABVX 83.23
- CVAC 52.38
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.